MARKHAM, ON, Oct. 17, 2017 /CNW/ - MedReleaf Corp. (TSX:LEAF)
("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP
certified producer of medical cannabis, welcomes and supports the
clarity provided by the Staff Notice issued by the Toronto Stock
Exchange ("TSX") on October 16, 2017
which the Company believes levels the playing field for listed
cannabis issuers in Canada.
Since its listing, MedReleaf has been and continues to operate
with the goal of being at all times fully compliant with the TSX
requirements pursuant to Sections 306, Section 325, and Part VII
(collectively the "Requirements") in the TSX Company Manual and is
confident that the review and enforcement of the Staff Notice will
have no impact on its operations or listing on the TSX.
"The TSX Staff Notice removes the uncertainty for issuers that
were already adhering to the Requirements and validates our
strategy of focusing on markets that are federally legal and offer
federal regulatory guidelines," said Neil
Closner, CEO of MedReleaf. "Until there is further
clarity on the U.S. market at the federal level, we will focus on
growth areas within Canada and
elsewhere in the world that have federal regulations in place,
minimizing risk to the business and our shareholders."
About MedReleaf Corp.
MedReleaf sets The Medical Grade
Standard™ for cannabis in Canada and around the world. The first
and only ICH-GMP and ISO 9001 certified cannabis producer in
North America, MedReleaf is a
R&D-driven company dedicated to patient care, scientific
innovation, research and advancing the understanding of the
therapeutic benefits of cannabis. Sourced from around the
world and perfected in one of two state of the art facilities in
Ontario, MedReleaf delivers a
variety of premium products to patients seeking safe, consistent
and effective medical cannabis.
For more information on MedReleaf, its products, research and
how the company is helping patients #livefree, please visit
MedReleaf.com or follow @medreleaf
Forward Looking Statements
This press release contains "forward-looking information" within
the meaning of applicable Canadian securities legislation which are
based upon MedReleaf's current internal expectations, estimates,
projections, assumptions and beliefs and views of future events.
Forward-looking information can be identified by the use of
forward-looking terminology such as "expect", "likely", "may",
"will", "should", "intend", "anticipate", "potential", "proposed",
"estimate" and other similar words, including negative and
grammatical variations thereof, or statements that certain events
or conditions "may", "would" or "will" happen, or by discussions of
strategy. Forward-looking information include estimates, plans,
expectations, opinions, forecasts, projections, targets, guidance
or other statements that are not statements of fact.
Any forward-looking information speaks only as of the date on
which it is made, and, except as required by law, MedReleaf does
not undertake any obligation to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise. New factors emerge from
time to time, and it is not possible for MedReleaf to predict all
such factors. When considering these forward-looking statements,
readers should keep in mind the risk factors and other cautionary
statements in MedReleaf's Annual Information Form dated
June 27, 2017 and filed with the
applicable Canadian securities regulatory authorities on SEDAR at
www.sedar.com. The risk factors and other factors noted in
MedReleaf's Annual Information Form could cause actual events or
results to differ materially from those described in any
forward-looking information.
SOURCE MedReleaf Corp.